Factor XI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis

Factor XI inhibitors: a new option for the prevention and treatment of cancer-associated thrombosis

Venous thromboembolism (VTE) is a relatively common complication in cancer patients with potentially dire consequences. Anticoagulants are the mainstay of treatment of cancer-associated VTE. The anticoagulants most often used are low-molecular-weight heparin (LMWH) and direct oral factor (F) Xa inh...

Full description

Bibliographic Details
Main Authors: Marcello Di Nisio, Matteo Candeloro, Nicola Potere, Ettore Porreca, Jeffrey I. Weitz
Format: Article
Language:English
Published: PAGEPress Publications 2024-05-01
Series:Bleeding, Thrombosis and Vascular Biology
Subjects:
Anticoagulants
venous thromboembolism
cancer
factor XI
Online Access:https://www.btvb.org/btvb/article/view/118

Internet

https://www.btvb.org/btvb/article/view/118

Similar Items